This CPB is revised to state that (i) extended-release triptorelin (Triptodur) is considered medically necessary for true (central) precocious puberty; (ii) leuprolide (Lupron) is considered medically necessary for aggressive angiomyxoma of the vulva; (iii) goserelin (Zoladex) is considered medically necessary for recurrent premenstrual attacks of acute intermittent porphyria.  This CPB has also been revised to state that the following are considered experimental and investigational: (i) histrelin for suppression of onset of puberty in transgender adolescents, (ii) triptorelin for suppression of ovarian function in pre-menopausal women with Hodgkin’s lymphoma, and (iii) degarelix for use in in-vitro fertilization.